v3.26.1
Segment Reporting - Significant Segment Expenses (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Abstract]        
Sales $ 331,827 $ 409,268 $ 756,716 $ 750,532
Cost of sales (excluding depreciation expense) 142,436 158,171 301,042 275,437
Research and development expense       1,048,380
Other research and development expense [1]       3,334,521
Total research and development expense 1,946,878 1,414,429 3,256,279 4,382,901
Sales and marketing expense 1,293,998 984,977 2,609,753 1,893,544
General and administrative expense 1,931,578 1,616,972 3,713,968 3,339,685
Depreciation and amortization expense 82,811 86,285 165,081 171,138
Total operating expenses 5,255,265 4,102,663 9,745,081 9,787,268
Total other income (expense), net 597,644 (734,356) 5,667,277 (1,174,776)
Loss before income taxes (4,468,230) (4,585,922) (3,622,130) (10,486,949)
Income tax expense (benefit) 865 0 865 (4,188)
Net loss (4,469,095) (4,585,922) (3,622,995) $ (10,482,761)
Single Reportable Segment [Member]        
Segment Reporting [Abstract]        
Sales 331,827 409,268 756,716  
Cost of sales (excluding depreciation expense) 142,436 158,171 301,042  
Research and development expense 616,014 89,217 1,054,814  
Other research and development expense [1] 1,330,864 1,325,212 2,201,465  
Total research and development expense 1,946,878 1,414,429 3,256,279  
Sales and marketing expense 1,293,998 984,977 2,609,753  
General and administrative expense 1,931,578 1,616,972 3,713,968  
Depreciation and amortization expense 82,811 86,285 165,081  
Total operating expenses 5,255,265 4,102,663 9,745,081  
Total other income (expense), net 597,644 (734,356) 5,667,277  
Loss before income taxes (4,468,230) (4,585,922) (3,622,130)  
Income tax expense (benefit) 865 0 865  
Net loss $ (4,469,095) $ (4,585,922) $ (3,622,995)  
[1] Other research and development expense include clinical affairs, regulatory, manufacturing and quality assurance expenses.